Cargando…
Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma
Current clinical and observational evidence supports the EXTREME regimen as one of the standards of care for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) followed by the administration of immune checkpoint inhibitors (ICIs). In addition to the inhibition of the...
Autores principales: | Okuyama, Kohei, Naruse, Tomofumi, Yanamoto, Souichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161653/ https://www.ncbi.nlm.nih.gov/pubmed/37143088 http://dx.doi.org/10.1186/s13046-023-02691-4 |
Ejemplares similares
-
Prolonged cetuximab treatment promotes p27(Kip1)-mediated G1 arrest and autophagy in head and neck squamous cell carcinoma
por: Okuyama, Kohei, et al.
Publicado: (2021) -
TMEM16A as a potential treatment target for head and neck cancer
por: Okuyama, Kohei, et al.
Publicado: (2022) -
Relationship between Tumor Budding and Partial Epithelial–Mesenchymal Transition in Head and Neck Cancer
por: Okuyama, Kohei, et al.
Publicado: (2023) -
Cell-in-cell structure in cancer: evading strategies from anti-cancer therapies
por: Okuyama, Kohei, et al.
Publicado: (2023) -
Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab-resistant oral squamous cell carcinoma
por: Tsuchihashi, Hiroki, et al.
Publicado: (2020)